Clinuvel Unveils Proprietary AI Tool to Strengthen Phase III Vitiligo Trial
Clinuvel unveils proprietary AI tool at America’s largest dermatology conference
Clinuvel Pharmaceuticals has showcased its programs at the American Academy of Dermatology (AAD) Annual Meeting in Denver, running from 27-31 March 2026. The event, expected to draw 20,000+ dermatology professionals, features the company’s melanocortin programs targeting vitiligo treatment development and SCENESSE for erythropoietic protoporphyria (EPP). The headline announcement is the unveiling of the Vitiligo Visual Algorithm (VVA), a proprietary artificial intelligence tool developed entirely in-house.
When big ASX news breaks, our subscribers know first
What is the Vitiligo Visual Algorithm?
The VVA represents a significant technical development in vitiligo clinical assessment. The AI-driven tool objectively evaluates pigmentation using standardised clinical photographs, tracking individual patient treatment progress over time. Development began in 2025 following extensive feedback from vitiligo experts involved in Clinuvel’s programs.
The company is currently deploying the VVA alongside its ongoing CUV105 vitiligo study, with plans to include the tool in the protocol of its upcoming CUV107 Phase III study. By seeking feedback from the dermatology community at AAD, Clinuvel aims to refine the algorithm whilst it continues training.
Standardised clinical assessment tools serve a critical function in regulatory submissions. Objective measurement reduces variability in trial endpoints, strengthening data credibility and potentially de-risking Phase III outcomes. This differentiates Clinuvel’s approach from conventional subjective assessment methods used in dermatological trials.
Key features of the VVA include:
- AI-driven analysis of clinical images
- Uses standardised clinical photographs
- Tracks individual patient progress over time
- Currently training alongside CUV105 study
- Planned for inclusion in CUV107 Phase III protocol
Pavilion of Photomedicine reimagined for 2026
Clinuvel’s physical exhibition presence at AAD has been substantially expanded for this year’s event. The Pavilion of Photomedicine, first launched at the 2025 AAD Meeting, has been completely reimagined to occupy 4,000 square feet of dedicated exhibition space.
The pavilion is designed to differentiate Clinuvel’s patient-centric drug development approach through immersive storytelling. The enclosed environment takes attendees through the company’s scientific heritage, patient focus, and future vision across three key areas: patient stories, academic engagement, and development heritage.
This direct engagement strategy with prescribing dermatologists supports both EPP commercial awareness and vitiligo pipeline visibility. The scale of investment in conference presence signals management’s prioritisation of physician education and relationship building in North American markets.
Satellite symposia deliver real-time expert feedback
Clinuvel presented results at three satellite symposia on 26 March, the day before the main conference commenced:
- Photodermatology Society 35th Annual Meeting
- Global Vitiligo Foundation Annual Symposium
- Skin of Colour Society Scientific Symposium
The company has supported all three expert meetings as part of its ongoing commitment to academic engagement.
Dr Linda Teng, Head of North American Operations
“The feedback from satellite symposia is invaluable to our teams as we can see our programs and data discussed in real-time by the real experts in the field. This gives us the opportunity to refine our approaches as well as anticipate potential issues before they occur.”
The next major ASX story will hit our subscribers first
What this means for investors
The AAD program represents a multi-layered commercialisation and clinical development strategy. The VVA development connects directly to Clinuvel’s broader vitiligo commercialisation ambitions, as objective assessment tools can support regulatory endpoints and strengthen Phase III trial protocols.
SCENESSE remains the only FDA-approved treatment for EPP, positioning Clinuvel for continued commercial growth as patient awareness increases. Dr Teng noted significant physician demand for vitiligo treatment options, stating that interest in the commercial program for EPP continues to grow as patients seek approved therapy.
| Element | Fact | Investor Relevance |
|---|---|---|
| VVA Tool | Proprietary AI assessment developed in-house | Potential differentiation in Phase III vitiligo trials through standardised clinical endpoints |
| CUV107 | Phase III study planned to include VVA in protocol | Next major clinical catalyst for vitiligo program |
| AAD Reach | 20,000+ dermatology professionals attending | Maximises commercial and clinical program visibility amongst key opinion leaders |
| SCENESSE | Only FDA-approved EPP treatment | Ongoing commercial growth opportunity in established market |
Dr Linda Teng, Head of North American Operations
“We know there is great demand from physicians who wish to offer more to their vitiligo patients, while interest in our commercial program for EPP continues to grow as patients seek approved therapy.”
The CUV107 Phase III study represents the next major milestone in Clinuvel’s vitiligo development pathway. The integration of the VVA tool into this protocol could provide competitive advantage through more robust clinical data collection and analysis capabilities compared to conventional assessment methods.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements break.